CLINICAL_TRIALS
trial_result
· 2017-10-26
Clinical Trial Update: Reirradiation and Erbitux in the HNSCC [Phase 2]
Summary
Phase 2 clinical trial evaluating reirradiation with cetuximab in head and neck squamous cell carcinoma has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Groupe Oncologie Radiotherapie Tete et Cou | Conditions: Head and Neck Cancer Squamous Cell | Phase 2 | Status: COMPLETED